%0 Journal Article %J Oncotarget %D 2015 %T The anti-leukemic activity of sodium dichloroacetate in p53mutated/null cells is mediated by a p53-independent ILF3/p21 pathway. %A Agnoletto, Chiara %A Brunelli, Laura %A Melloni, Elisabetta %A Pastorelli, Roberta %A Casciano, Fabio %A Rimondi, Erika %A Rigolin, Gian Matteo %A Cuneo, Antonio %A Secchiero, Paola %A Zauli, Giorgio %X

B-chronic lymphocytic leukemia (B-CLL) patients harboring p53 mutations are invariably refractory to therapies based on purine analogues and have limited treatment options and poor survival. Having recently demonstrated that the mitochondria-targeting small molecule sodium dichloroacetate (DCA) exhibits anti-leukemic activity in p53wild-type B-CLL cells, the aim of this study was to evaluate the effect of DCA in p53mutated B-CLL cells and in p53mutated/null leukemic cell lines. DCA exhibited comparable cytotoxicity in p53wild-type and p53mutated B-CLL patient cell cultures, as well as in p53mutated B leukemic cell lines (MAVER, MEC-1, MEC-2). At the molecular level, DCA promoted the transcriptional induction of p21 in all leukemic cell types investigated, including p53null HL-60. By using a proteomic approach, we demonstrated that DCA up-regulated the ILF3 transcription factor, which is a known regulator of p21 expression. The role of the ILF3/p21 axis in mediating the DCA anti-leukemic activity was underscored by knocking-down experiments. Indeed, transfection with ILF3 and p21 siRNAs significantly decreased both the DCA-induced p21 expression and the DCA-mediated cytotoxicity. Taken together, our results emphasize that DCA is a small molecule that merits further evaluation as a therapeutic agent also for p53mutated leukemic cells, by acting through the induction of a p53-independent pathway.

%B Oncotarget %V 6 %P 2385-96 %8 2015 Feb 10 %G eng %N 4 %1 http://www.ncbi.nlm.nih.gov/pubmed/25544776?dopt=Abstract %R 10.18632/oncotarget.2960 %0 Journal Article %J J Immunol Res %D 2014 %T Modulation of circulating cytokine-chemokine profile in patients affected by chronic venous insufficiency undergoing surgical hemodynamic correction. %A Tisato, Veronica %A Zauli, Giorgio %A Gianesini, Sergio %A Menegatti, Erica %A Brunelli, Laura %A Manfredini, Roberto %A Zamboni, Paolo %A Secchiero, Paola %K Adult %K Aged %K Chemokines %K Chronic Disease %K Cytokines %K Female %K Hemodynamics %K Humans %K Male %K Middle Aged %K Saphenous Vein %K Varicose Veins %K Venous Insufficiency %X

The expression of proinflammatory cytokines/chemokines has been reported in in vitro/ex vivo settings of chronic venous insufficiency (CVI), but the identification of circulating mediators that might be associated with altered hemodynamic forces or might represent innovative biomarkers is still missing. In this study, the circulating levels of 31 cytokines/chemokines involved in inflammatory/angiogenic processes were analysed in (i) CVI patients at baseline before surgical hemody namic correction, (ii) healthy subjects, and (iii) CVI patients after surgery. In a subgroup of CVI patients, in whom the baseline levels of cytokines/chemokines were analyzed in paired blood samples obtained from varicose vein and forearm vein, EGF, PDGF, and RANTES were increased at the varicose vein site as compared to the general circulation. Moreover, while at baseline, CVI patients showed increased levels of 14 cytokines/chemokines as compared to healthy subjects, 6 months after surgery, 11 cytokines/chemokines levels were significantly reduced in the treated CVI patients as compared to the CVI patients before surgery. Of note, a patient who exhibited recurrence of the disease 6 months after surgery, showed higher levels of EGF, PDGF, and RANTES compared to nonrecurrent patients, highlighting the potential role of the EGF/PDGF/RANTES triad as sensitive biomarkers in the context of CVI.

%B J Immunol Res %V 2014 %P 473765 %8 2014 %G eng %1 http://www.ncbi.nlm.nih.gov/pubmed/24741602?dopt=Abstract %R 10.1155/2014/473765 %0 Journal Article %J Oncotarget %D 2014 %T Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3. %A Agnoletto, Chiara %A Melloni, Elisabetta %A Casciano, Fabio %A Rigolin, Gian Matteo %A Rimondi, Erika %A Celeghini, Claudio %A Brunelli, Laura %A Cuneo, Antonio %A Secchiero, Paola %A Zauli, Giorgio %K Aged %K Aged, 80 and over %K Dichloroacetic Acid %K Drug Synergism %K Female %K Humans %K Imidazoles %K Leukemia, Lymphocytic, Chronic, B-Cell %K Male %K Middle Aged %K Piperazines %K Tumor Suppressor Protein p53 %X

The anti-leukemic activity of the mitochondria-targeting small molecule sodium dichloroacetate (DCA), used alone and in association with the small molecule inhibitor of the p53/MDM2 interaction Nutlin-3, was analyzed in primary B-chronic lymphocytic leukemia (B-CLL) samples (n=22), normal peripheral blood cells (n=10) and in p53wild-type EHEB, JVM-2, JVM-3 B lymphoblastoid cell lines. DCA exhibited a dose-dependent anti-leukemic activity in both primary B-CLL and B leukemic cell lines with a functional p53 status and showed a synergistic cytotoxic activity when used in combination with Nutlin-3. At the molecular level, DCA positively regulated p53 activity, as documented by post-transcriptional modifications of p53 protein and synergized with Nutlin-3 in increasing the expression of the p53-target genes MDM2, PUMA, TIGAR and in particular p21. The potential role of p21 in mediating the DCA+Nutlin-3 anti-leukemic activity was underscored in knocking-down experiments. Indeed, transfection of leukemic cells with p21 siRNAs significantly decreased the DCA+Nutlin-3-induced cytotoxicity. Taken together, our data emphasize that DCA is a molecule that merits to be further evaluated as a chemotherapeutic agent for B-CLL, likely in combination with other therapeutic compounds.

%B Oncotarget %V 5 %P 4347-60 %8 2014 Jun 30 %G eng %N 12 %1 http://www.ncbi.nlm.nih.gov/pubmed/24962518?dopt=Abstract